6 results about "Sustained release dosage forms" patented technology

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the same, are disclosed. 20 24 20 28 77 01 M ay 2 02 4 A B S T R A C T 2 0 2 4 2 0 2 8 7 7 0 1 M a y 2 0 2 4

A preparation method of a luteolin nano slow-release dosage form belongs to the field of food and medicine, and the specific scheme comprises the following steps: step 1, dissolving luteolin and carnosic acid in a mixed solvent of dichloromethane and methanol to obtain a solution A; step 2, adding the solution A into a polyvinyl alcohol aqueous solution I, and performing ultrasonic treatment to form an emulsion B; step 3, dropwise adding the emulsion B into a polyvinyl alcohol aqueous solution II, and stirring at room temperature to obtain a suspension C; and 4, carrying out centrifugal separation on the suspension C, and washing the precipitate to obtain the luteolin nano stable slow-release dosage form. The luteolin nano stable slow-release dosage form prepared by the invention has the advantages of good water solubility, high loading rate and the like, and can effectively improve the water solubility and slow-release performance of natural micromolecular luteolin in practical application.

The present invention provides delayed-release dosage forms and boluses configured for administration to animals. It also provides the use of the delayed-release dosage forms or boluses of the present invention to reduce methane production in ruminants. Methods for producing the boluses of the present invention are also provided. [Solution] A delayed-release dosage form or bolus configured for administration to an animal, wherein the dosage form and the bolus are configured to release a hydrophobic substance to the animal over a period of time.

The present invention relates to a solid oral pharmaceutical for Axitinib, Ibrutinib and / or Palbociclib (API) or any other Kinase Inhibitor API with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Axitinib, Ibrutinib and / or Palbociclib and other Kinase Inhibitors can be found for treatment of malign tumor diseases and others.

The invention relates to a wild ginseng peptide-ganoderma lucidum spore oil compounded anti-aging soft capsule, which is prepared by synergistically compounding a plurality of mitochondrial nutrients according to a scientific proportion, and supplementing high-purity raw materials and slow-release dosage forms, so that energy metabolism activation and anti-oxidation synergistic intervention are realized; therefore, the anti-aging capsule systematically delays aging through multi-target regulation and control of mitochondrial functions. The wild ginseng peptide soft capsule is characterized by comprising the following components in parts by mass: 50-150 parts of wild ginseng peptide, 30-100 parts of ganoderma lucidum spore oil, 20-60 parts of an oil carrying agent, 5-20 parts of soybean phospholipid and 5-15 parts of gamma-cyclodextrin, the soft capsule shell is prepared from gelatin, glycerol and purified water, and the mass ratio of the gelatin to the glycerol to the purified water is 1: (0.6-0.8): (1.2-2.5).